Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01496170
First received: December 6, 2011
Last updated: October 21, 2014
Last verified: October 2014

December 6, 2011
October 21, 2014
December 2011
June 2012   (final data collection date for primary outcome measure)
Mean population Inhibitory Concentration for 50% Effect (IC50) in cerebral spinal fluid (CSF) ß-amyloid peptide 40 (Aß40) [ Time Frame: Hour 0 (predose) to 36 hours post-dose on Day 7 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01496170 on ClinicalTrials.gov Archive Site
  • Change in CSF Aß40 concentration determined by time-weighted average from 0 to 24 hours (TWA0-24) [ Time Frame: Baseline, and assessment over 24 hours post Day 7 dose ] [ Designated as safety issue: No ]
  • Change in CSF soluble amyloid precursor protein ß (sAPPß ) concentration determined by TWA0-24 [ Time Frame: Baseline, and assessment over 24 hours post Day 7 dose ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])
A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)]

This study will assess the safety and pharmacodynamics of three different doses of MK-8931, a ß-secretase inhibitor, in participants with mild to moderate Alzheimer's Disease (AD).

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: MK-8931
    MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
    Other Name: SCH 900931
  • Drug: Placebo
    Placebo capsules, orally, once per day for 7 days
  • Experimental: Treatment A: MK-8931 12 mg
    Participants receiving 12 mg MK-8931 for 7 days
    Intervention: Drug: MK-8931
  • Experimental: Treatment B: MK-8931 40 mg
    Participants receiving MK-8931 40 mg for 7 days
    Intervention: Drug: MK-8931
  • Placebo Comparator: Treatment C: Placebo matching MK-8931 12 mg or 40 mg
    Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
    Intervention: Drug: Placebo
  • Experimental: Treatment D: MK-8931 60 mg
    Participant receiving MK-8931 60 mg for 7 days
    Intervention: Drug: MK-8931
  • Placebo Comparator: Treatment E: Placebo matching MK-8931 60 mg
    Participants receiving placebo matching MK-8931 60 mg for 7 days
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Body Mass Index (BMI) between 18 and 35
  • Mild to moderate Alzheimer's Disease (AD)
  • Clear history of cognitive and functional decline over at least one year that is either documented in medical records, or documented by history from an informant who knows the subject well
  • Magnetic Resonance Image (MRI) scan consistent with a diagnosis of AD
  • Ability to read at a 6th grade level and history of academic achievement and/or employment sufficient to exclude mental retardation
  • If applicable, on a stable dose of an acetylcholinesterase inhibitor and/or memantine for at least the last 3 months before Screening, and willing to remain on the same dose for the duration of the trial
  • Reliable trial partner/caregiver
  • Willing to provide a blood sample for Apolipoprotein E (APOE) genotyping
  • In general good health (other than AD)
  • Participant capable of conceiving and/or participant with partner capable of conceiving willing to use a medically acceptable form of contraception during the trial and for 3 months after stopping the medication

Exclusion criteria:

  • History (within 2 years of the prestudy visit) or current evidence of any neurological or neurodegenerative disorder other than AD that is associated with transient or sustained alterations in cognition
  • Clinically significant abnormalities in serum vitamin B12, folate, thyroid stimulating hormone (TSH) or thyroxin 4 (T4). Vitamin B12 or thyroid replacement therapy must with stable dose for at least 2 months prior to screening visit
  • One or more pre-existing risk factors for Torsades de Pointes: New York Heart Association (NYHA) Functional Classification II through IV heart failure; Familial Long QT Syndrome; or Uncorrected hypokalemia
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
  • History of spinal cord compression or any other current abnormalities in the lumbar region (skin infection, developmental abnormalities in lower spine, etc.)
  • History of any infectious disease within 4 weeks prior to drug administration
  • Human immunodeficiency virus (HIV) positive
  • History of hepatitis or liver disease within 6 months of screening
  • History of psychiatric or personality disorders
  • Evidence of suicidality or is at risk for self-harm or harm to others
  • History of seizures or epilepsy or anticonvulsant use within the last 5 years before Screening
  • History of alcohol or drug abuse in the past 2 years
  • Donation of blood in the past 60 days
  • Previously received the study drug
  • Currently participating in another clinical study or have participated in a clinical study (e.g., laboratory or clinical evaluation) within 30 days of baseline
  • Member of the study staff or family members of the study staff
  • Demonstrated allergic reactions (e.g., food, drug, atopic reactions or asthmatic episodes)
  • History of malignancy occurring within the 5 years immediately before Screening, except for a subject who has been adequately treated for basal cell or squamous cell skin cancer, in situ cervical cancer, localized prostate carcinoma; or has undergone potentially curative therapy with no evidence of recurrence for ≥1 year post-therapy, and deemed at low risk for recurrence by her/his treating physician
Both
50 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01496170
P07820, MK-8931-010
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP